About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.
All News
Advertisement
Advertisement
Your daily dose of the clinical news you may have missed.
A quick review of the scope of diabetes in the US and of the gaps in equitable access to care supports the annual call to action from the International Diabetes Federation.
The CDC just released its annual STD surveillance report. Are you caught up on the latest trends? Try your hand at these 7 questions to find out.
Your daily dose of the clinical news you may have missed.
More than 2.4 million STIs were reported in the US in 2023 — a 1.8% decrease from 2022, according to the CDC's annual STI report.
Little action has been taken by state medical boards against clinicians who spread unsubstantiated claims about COVID-19, vaccines, or other pandemic-related topics.
Your daily dose of the clinical news you may have missed.
Michigan Medicine researchers found that at all age levels, women with known/suspected OSA were more likely than men to be diagnosed with dementia.
The FDA cleared Novavax to start enrolling the planned phase 3 trial after a safety concern was found to be unrelated to the combination vaccine.
Advertisement
The 11 words and phrases, among others, are often automatic responses from clinicians in highly emotional settings of severe illness. Find 11 alternatives, here.
Your daily dose of the clinical news you may have missed.
Find details on the surge in US pertussis cases, the first self-administered flu vaccine, and study findings underscoring the evolving nature of long COVID.
AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.
AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.
A 25-year study of the Lothian Birth Cohorts found that childhood intelligence, lifestyle factors, and brain health significantly impact cognitive aging and longevity.
A decision on ending use of oral phenylephrine as a nasal decongestant in OTC products will be made following public comment on FDA's proposed order.
Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.
The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.
Your daily dose of the clinical news you may have missed.
Advertisement
Advertisement
Advertisement